Wednesday, November 6th 2019 at 4:44pm UTC DUBLIN–(BUSINESS WIRE)– The « Innovations in T Cells, Semiconductors, Vaccines, Machine Learning, and Recombinant Proteins » report has been added to ResearchAndMarkets.com’s offering. This edition of the Inside R&D TechVision Opportunity Engine (TOE) features trends and innovations in the field of cancer and tumor therapy, …
Plus »VIQ Solutions Reports Q3 Earnings
Wednesday, November 6th 2019 at 9:00pm UTC Earnings Reaffirm Positive Trajectory PHOENIX–(BUSINESS WIRE)– VIQ Solutions Inc. (“VIQ” or the “Company”) (TSX Venture Exchange: VQS and OTC Markets: VQSLF) a global provider of secure, AI-driven, digital voice and video capture technology and services for law enforcement, legal, insurance, courts, and transcription …
Plus »Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights
Wednesday, November 6th 2019 at 9:05pm UTC –Webcast and conference call today at 4:30 p.m. ET– BRISBANE, Calif.–(BUSINESS WIRE)– Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2019 and provided …
Plus »Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019
Wednesday, November 6th 2019 at 9:47pm UTC First patient dosed with UCARTCS1 in MELANI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory Multiple Myeloma Patient screening ongoing with UCART22 in BALLI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Grant of a new IND for UCART123 following a …
Plus »Baxter to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Wednesday, November 6th 2019 at 9:45pm UTC DEERFIELD, Ill.–(BUSINESS WIRE)– Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 2nd Annual HealthCONx Conference in Boston on December 4, 2019. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:15 a.m. Eastern …
Plus »Ultivue Expands UltiMapper™ Portfolio of Multiplex Marker Assays for Comprehensive Phenotyping of the Immune Microenvironment and Tissue Immuno-Profiling Research
Wednesday, November 6th 2019 at 2:35pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ultivue, a leading developer of tissue biomarker identification and quantification assays for translational research and pathology labs, today announced the expansion of its UltiMapper™ multiplex immunofluorescence kit portfolio with a T-reg and MDSC kit. The UltiMapper I/O T-reg kit identifies …
Plus »ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting
Wednesday, November 6th 2019 at 2:01pm UTC Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and BPDCN Preclinical Data for IMGN632 in Combination with Azacitidine and Venetoclax Support Clinical Evaluation of Doublets and Triplet in AML WALTHAM, Mass.–(BUSINESS WIRE)– …
Plus »Quanterix Corporation Releases Operating Results for Third Quarter 2019
Wednesday, November 6th 2019 at 9:01pm UTC Strong revenue growth and successful early launch of new HD-X Analyzer BILLERICA, Mass.–(BUSINESS WIRE)– Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three and nine months ended September 30, …
Plus »Akoya Biosciences to Showcase New Multiplexed Imaging Data From Its Spatial Biology Platforms at SITC 2019
Wednesday, November 6th 2019 at 5:05pm UTC Company and customer data will highlight the importance of using spatially resolved biomarker analysis for cancer immunotherapy studies MENLO PARK, Calif.–(BUSINESS WIRE)– Akoya Biosciences, Inc., The Spatial Biology Company™, announced today that data generated with its CODEX® and Phenoptics™ multiplex immunofluorescence platforms will …
Plus »Sigilon Therapeutics to Present Preclinical Data Showing Six Months Durability for Cell Therapies in Rare Blood Disorders
Wednesday, November 6th 2019 at 2:00pm UTC Data to be presented next month at the American Society of Hematology Annual Meeting CAMBRIDGE, Mass.–(BUSINESS WIRE)– Sigilon Therapeutics announced today that it will present data at the American Society of Hematology Annual Meeting demonstrating that its novel Shielded Living TherapeuticsTM platform for …
Plus »